In the evolving field of biochemical research, specific molecular structures often garner significant attention due to their unique properties. Among these, the GV1001 peptide sequence stands out as a subject of intense scientific inquiry. Often categorized as a synthetic telomerase-specific peptide vaccine, it represents a precise arrangement of building blocks that researchers utilize to explore various biological interactions.
Molecular Architecture of GV1001
At its core, GV1001 is a 16-amino-acid peptide. This specific chain is derived from the catalytic site of the human telomerase reverse transcriptase (hTERT) protein, specificall hTERT peptide fragment GV1001 demonstrates - PubMed y spanning residues 611–626. The structural integrity of this molecule is defined by the following 16-aa hTERT sequence:
H-Glu-Ala-Arg-Pro-Ala-Leu-Leu-Thr-Ser-Arg-Leu-Arg-Phe-Ile-Pro-Lys
This precise amino acid arrangement is what distinguishes the molecule in laboratory settings. Because GV1001 is a 16-amino acid peptide sequence of hTERT protein, it has become a standard reference point for those studying the functional properties of telomerase-derived structures.
Scientific Context and Research Applications
When reviewing literature or laboratory datasets, one will often encounter GV1001 in the context of advanced biochemical studies. It is important to note that GV1001 is a 16-amino-acid peptide that has been extensively documented in academic databases like PubMed and PMC. Beyond its primary classification, GV1001 is a vaccine peptide derived from a 16-amino-acid sequence from the active site of the enzyme, which allows researchers to investigate its potential in various experimental models.
For those interested in the technical nomenclature, the substance is also known as tertomotide. Whether referred to as peptide GV1001 or by its synonym, the molecule consistently displays the same 16-aa human telomerase reverse transcriptase (hTERT) sequence.
Key Characteristics:
* Structure: A linear chain of 16 amino acids.
* Origin: Derived from the hTERT protein (residues 611–626).
* Classification: Often investigated as a synthetic telomerase-specific peptide vaccine.
* Synonyms: Known in various research archives as RIAVAX (also known as GV1001) or tertomotide.
Navigating Research Data
When analyzing GV1001 peptide treatmen GV1001 peptide. Not For Human Use, Lab Use Only. Cat.#: 319567. Size: 5.0 Sequence.H-Glu-Ala-Arg-Pro-Ala-Leu-Leu-Thr-Ser-Arg-Leu-Arg-Phe-Ile-Pro-LysRead more t datasets, researchers often focus on the specific sequences involved in protein-protein interactions. The GV1001; hTERT (611–626) designation is frequently used to ensure accuracy when documenting experimental conditions.
It is Tertomotide (also known as GV1001)is a synthetic telomerase-specific peptide vaccinepatented by Norsk Hydro Asa for the cancer treatment.Read more noteworthy that GV1001 is a 16-amino by JH Kim·2025·Cited by 1—Data Article. Transcriptomic and functional annotation datasets forGV1001 peptide treatmentin an experimental autoimmune encephalomyelitis mouse model.Read more acid peptide that exhibits high specificity. In many studies, GV1001, a 16-mer peptide, is utilized to observe how such a small structure can influence biological pathways. Because GV1001 is a 16-amino-acid vaccine peptide, it serves as a foundational tool for those exploring the mechanisms of telomerase inhibition or modulation in non-human, controlled environments.
Conclusion
The study of peptide Tertomotide is a syntheticpeptidevaccine, containing 16amino acidresidues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), Read more structures requires a deep understanding of primary sequences and their functional implications. As a peptide consisting of 16 amino acids, GV1001 offers a clear, quantifiable subject for biochemical analysis. While many recognize it as GV1001, an anticancer vaccine in its historical context, modern research continues to uncover its diverse roles in experimental biology. By focusing on the precise 16-aa hTERT sequence, scientists can continue to refine their approach to utilizing this unique peptide in various laboratory application Tertomotide is apeptidevaccine that targets telomerase, being developed by KAEL-GemVax, for the treatment of Alzheimer's disease, benign prostatic. s.
*Note: This information is provided for educational and research-related purposes only. GV 10 Feb 2026—Originally developed as a cancer vaccine,GV1001 is a 16-amino-acid peptidecomprising a sequence from the human enzyme telomerase reverse Read more 1001 is a chemical compound intended for laboratory use, not for human consumption or medical treatment.*